Table 1 Characteristics of eligible studies in this meta-analysis
Author, year | country | recruiting year | Adipokines and test method | sample size, n | sex, n, male (female) | age, mean (SD) | BMI kg/m2 (Mean ± SD) | Diagnostic criteria | study design | source of control | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
case | control | case | Control | Case | control | Case | control | |||||||
Alexandrakis 2004 [24] | Greece | NR | leptin (ELISA) | 62 | 20 | 32(30) | sex-matched | 68.3 | age-matched | 26.6±4.3 | NR | Durie and Salmon criteria | case control | NR |
Dalamaga 2009 [26] | Greece | 18/1/2001 - 25/8/ 2007 | leptin, resistin, adiponectin (ELISA) | 73 | 73 | 42(31) | 42(31) | 67.1(5.9) | 68.0(5.8) | 27.7±4.0 | 26.2±4.2 | Durie and Salmon criteria | case control | hospital |
Hofmann 2012 [27] | USA | 1993 - 2001 | leptin, adiponectin (ELISA) | 174 | 348 | 112(62) | 224(124) | 64.0 | 64.0 | 27.7±5.2 | 27.2±4.5 | NR | nested case control | population |
Hofmann 2016 [29] | USA | NR | adiponectin (ELISA) | 627 | 1246 | 269(355) | 538(708) | 63.9(7.0) | 63.9(7.0) | 27.4±5.0 | 27.2±4.9 | NR | nested case control | population |
Liu 2020 [32] | China | NR | leptin, adiponectin, visfatin (ELISA) | 39 | 20 | 24(15) | 11(9) | 63.4(8.4) | 66.7(4.8) | NR | NR | International Myeloma Working Group | case control | hospital |
Pamuk 2006 [25] | Turkey | NR | leptin, resistin (ELISA) | 14 | 25 | 8(6) | 15(10) | 60.7(9.5) | 54.5(12.0) | 26.7±3.8 | 25.4±3.4 | Durie and Salmon criteria | case control | hospital |
Santo 2017 [31] | USA | NR | resistin (ELISA) | 178 | 358 | 129(49) | 258(100) | 63.0(7.8) | 63.0(7.8) | 26.9±4.0 | 26.5±4.2 | NR | nested case control | population |
Yu 2016 [30] | China | NR | leptin, adiponectin, visfatin, resistin (ELISA) | 28 | 28 | 15(13) | 15(13) | 56.0(10.0) | 55.0(12.0) | 22.8±3.1 | 23.0±2.8 | International Myeloma Working Group | case control | hospital |
Esheba 2014 [28] | Egypt | 10/2011 - 10/2013 | leptin, resistin (ELISA) | 16 | 16 | 6(10) | 6(10) | 55.7(3.5) | 55.5(4.0) | ≤24.9 (non-obesity) | WHO diagnostic criteria | case control | Hospital | |
Salman 2020 [33] | Iraqi | 10/2018 – 5/2019 | Resistin (ELISA) | 58 | 24 | 36(22) | 15(9) | 56.32 | 55.43 | 28.2 | 25.9 | NR | Case control | Hospital |